Review of endocrine disorders in the U.S.

A dogged review of the medical literature has produced what is believed to be the nation's first comprehensive estimate of the extent of dozens of endocrine disorders in the United States. 

Unsurprisingly, say the Johns Hopkins researchers who gathered the data, obesity and related conditions including metabolic syndrome and diabetes were the most common disorders and had the highest  estimated rate of new cases per year -- what experts call "prevalence" and "incidence" respectively.  However, the review also shed light on the significant impact that several other conditions have at the population level, such as osteoporosis.  Surprisingly, the researchers say, their review showed that this bone-thinning condition appears to affect men and women nearly equally, with about seven percent prevalence for both sexes.

Health professionals have long assumed that osteoporosis occurs primarily in women after menopause, as a consequence of estrogen hormone loss.

"Endocrinologists confidently talk about how common or uncommon certain hormone-related conditions are, but we were lacking the hard numbers. Now we have compiled real data based on U.S.-based clinical studies," says Sherita Hill Golden, M.D., M.H.S., associate professor in the division of endocrinology at the Johns Hopkins University School of Medicine.

Golden says many endocrine disorders appear to be on the rise in the U.S. and around the world, but scientists have never amassed hard numbers in a unified source of prevalence or risk as they have for such medical conditions cancer and heart disease.

"Without such information, it's hard to get public health decision makers to focus on all endocrine disorders, develop preventive strategies, and allocate the right level of funding for research and treatment," Golden says.

To address the lack of information, Golden and her colleagues searched medical article databases for prevalence and incidence data for 54 endocrine disorders with both clinical and public health significance, identifying 2268 studies.  They concentrated on the most recent (since 1998) 70 articles that had the most rigorous data on the general population, as opposed to studies involving small groups of patients from specialty clinics that see higher numbers of endocrine disorders. 

Reporting In the June Journal of Clinical Endocrinology and Metabolism, Golden and her colleagues found, as expected, that obesity-related diseases such as diabetes were the most common endocrine disorders in the U.S., with 25 to 28 percent of the U.S. population being clinically obese and 10 percent having type-2 diabetes.  The review suggests that more than a third of the population has metabolic syndrome, a collection of obesity-related conditions including blood fat disorders, insulin resistance and the presence of inflammatory proteins that increase the risk for heart disease and stroke.

The review also found that type-1 diabetes and tumors of the pituitary gland are among the least common endocrine disorders, affecting less than one percent of the population. Golden notes that there is a general lack of multi-ethnic, multi-racial studies, research needed to determine variable risk in specific populations.

The study was funded by a grant from The Endocrine Society.

Other researchers who participated in this study include Karen A. Robinson, M.Sc., Ian Saldanha, M.B.B.S., M.P.H., Blaire Anton, M.L.I.S., M.S., and Paul W. Ladenson, M.D.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study finds skincare products could expose children to harmful phthalates